Silvercrest Asset Management Group LLC Grows Stock Position in Cerus Co. (NASDAQ:CERS)

Silvercrest Asset Management Group LLC raised its stake in shares of Cerus Co. (NASDAQ:CERS) by 4.4% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,696,560 shares of the biotechnology company’s stock after buying an additional 114,628 shares during the period. Silvercrest Asset Management Group LLC owned about 1.46% of Cerus worth $5,096,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Cerus by 4.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 8,982 shares during the last quarter. Neuberger Berman Group LLC purchased a new position in shares of Cerus during the 4th quarter valued at about $26,000. Russell Investments Group Ltd. raised its stake in shares of Cerus by 451.1% during the 1st quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 12,179 shares during the last quarter. Bouvel Investment Partners LLC grew its position in shares of Cerus by 4.7% during the 1st quarter. Bouvel Investment Partners LLC now owns 269,849 shares of the biotechnology company’s stock valued at $510,000 after acquiring an additional 12,224 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Cerus by 8.3% during the 4th quarter. SG Americas Securities LLC now owns 188,702 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 14,433 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald raised their target price on Cerus from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Craig Hallum started coverage on Cerus in a report on Friday, April 12th. They issued a “buy” rating and a $5.00 price objective on the stock.

Cerus Price Performance

CERS stock traded down $0.02 during trading on Tuesday, hitting $2.28. The stock had a trading volume of 456,452 shares, compared to its average volume of 1,256,697. The company has a current ratio of 2.41, a quick ratio of 1.72 and a debt-to-equity ratio of 1.29. The company’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.93. Cerus Co. has a twelve month low of $1.21 and a twelve month high of $3.08.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $38.37 million for the quarter, compared to analysts’ expectations of $36.40 million. Cerus had a negative net margin of 19.27% and a negative return on equity of 58.65%. As a group, equities research analysts anticipate that Cerus Co. will post -0.09 EPS for the current fiscal year.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.